<DOC>
	<DOCNO>NCT01324349</DOCNO>
	<brief_summary>The objective study evaluate safety effectiveness Covidien 's Hemostatic Patch control bleed hepatic surgery . The performance Hemostatic Patch compare Control adjunct conventional hemostatic technique .</brief_summary>
	<brief_title>Comparison Hemostatic Patch Fibrin Sealant ( TachoSil® ) Subjects Undergoing Hepatic Surgery</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Major Scheduled nonemergent , hepatic surgery Presence appropriate target bleed site ( TBS ) define protocol Major Subject undergo laparoscopic hepatic procedure Hemostatic Patch deliver applied trocar In subject documented history cirrhosis , subject uncorrected platelet count &lt; 60,000 per mm³ determine laboratory test perform immediately prior surgery Subject severe coagulopathy define INR &gt; 2.0 Subject Total Bilirubin &gt; 2.5mg/dL Subject active local infection Target Bleeding Site Study procedure involve liver transplant recipient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatic</keyword>
	<keyword>Topical Hemostat</keyword>
</DOC>